Local injection of infliximab in the postoperative recurrence of Crohn's disease
Authors:
- Micaela CretellaMCMicaela Cretella
- Claudio TostiCTClaudio Tosti
- Giampiero PalmieriGPGiampiero Palmieri
- Carmelina PetruzzielloCPCarmelina Petruzziello
- Alessandra GeremiaAGAlessandra Geremia
- Emma CalabreseECEmma Calabrese
- Francesco PalloneFPFrancesco Pallone
- 1 March 2006
- journal article
- clinical trial
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 63 (3) , 486-492
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Interleukin-21 enhances T-helper cell type I signaling and interferon-γ production in Crohn’s diseaseGastroenterology, 2005
- Balancing the risks and benefits of infliximab in the treatment of inflammatory bowel diseaseGut, 2004
- Infliximab for the Treatment of Fistulas in Patients with Crohn's DiseaseNew England Journal of Medicine, 1999
- Endoscopic and histological healing with infliximab anti–tumor necrosis factor antibodies in Crohn's disease: A European multicenter trialGastroenterology, 1999
- Tumor necrosis factor α antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitisGastroenterology, 1999
- Inflammatory bowel disease: Etiology and pathogenesisGastroenterology, 1998
- A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's DiseaseNew England Journal of Medicine, 1997
- Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cellsGastroenterology, 1997
- Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2)Gastroenterology, 1995
- Activation of peripheral blood and intestinal lamina propria lymphocytes in Crohn's disease. In vivo state of activation and in vitro response to stimulation as defined by the expression of early activation antigens.Gut, 1987